Trump’s push to bring drug manufacturing back to the United States has sparked concerns across the industry, particularly for generic drugmakers ... as the charts below show.

US & Canada, May 09, 2025 (GLOBE NEWSWIRE) -- According to a new comprehensive report from The Insight Partners, the global Generic Drugs Market is growing owing to patent expiry and loss of ...

Ottawa, Precedence Research, April 16, 2025 (GLOBE NEWSWIRE) -- According to Precedence Research, the worldwide generic drugs market size was valued at USD 445.62 billion in 2024 and is projected ...

This launch is part of Sunshine Biopharma’s efforts to expand its presence in Canada’s generic drugs market ... is also engaged in proprietary drug development, working on treatments for ...

Generic drugs tend to be less expensive, as they don’t cost as much to develop. This is because brand-name medications are new drugs that require research, development, and clinical trials.

"C-Path was built on the vision that no single entity can solve the challenges of the drug development process alone," said former C-Path CEO Dr. Woosley. "Over the last 20 years, C-Path has ...

Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity. Eslicarbazepine acetate tablets are the generic of Sumitomo Pharma America’s Aptiom.

Drug development is a notoriously slow, complex and costly process, with over 90% of drug candidates failing before reaching the market. A major cause of this inefficiency is the reliance on ...

Trump intends for more production of pharmaceuticals to move back to the United States, but tariffs may have the opposite effect for generic drugs, and at the same time increasing shortages and ...

Dr. Scott Gottlieb, former FDA Commissioner, joins 'Squawk Box' to discuss current pharmaceutical imports under investigation, moving production for branded and generic drugs elsewhere ...

Accomplished physician-scientist brings more than 30 years of industry leadership experience and CNS drug development expertise. SEATTLE, April 29, 2025 /PRNewswire/ -- Transneural Therapeutics ...

Generic drug manufacturers have had to contend with increasing competition and tight profit margins in recent years. Slapping extra costs through tariffs could undermine their ability to do ...